CoChat

Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells

Open access
Thompson, Ravyn M., Dytfeld, Dominik, Reyes, Leticia, Robinson, Reeder M., Smith, Brittany, Manevich, Yefim, Jakubowiak, Andrzej, Komarnicki, Mieczyslaw, Przybylowicz-Chalecka, Anna, Szczepaniak, Tomasz, Mitra, Amit K., Van Ness, Brian G., Luczak, Magdalena, Dolloff, Nathan G. · 2017 · Oncotarget
Cited by 126

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

// Ravyn M. Thompson 1 , Dominik Dytfeld 2 , Leticia Reyes 1 , Reeder M. Robinson 1 , Brittany Smith 1 , Yefim Manevich 1 , Andrzej Jakubowiak 3 , Mieczyslaw Komarnicki 2 , Anna Przybylowicz-Chalecka 2 , Tomasz Szczepaniak 2 , Amit K. Mitra 5 , Brian G. Van Ness 5 , Magdalena Luczak 4 , Nathan G. Dolloff 1, * 1 Department of Cell and Molecular Pharmacology & Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, USA 2 Karol Marcinkowski University of Medical Sciences, Poznan, Poland 3 University of Chicago, Chicago, IL, USA 4 Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland 5 University of Minnesota, Minneapolis, MN, USA * These authors contributed equally to this work Correspondence to: Nathan G. Dolloff, email: dolloffn@musc.edu Keywords: multiple myeloma, proteasome inhibitor, glutaminase, carfilzomib Received: December 08, 2016 Accepted: March 01, 2017 Published: March 16, 2017 ABSTRACT Curative responses in the treatment of multiple myeloma (MM) are limited by the emergence of therapeutic resistance. To address this problem, we set out to identify druggable mechanisms that convey resistance to proteasome inhibitors (PIs; e.g., bortezomib), which are cornerstone agents in the treatment of MM. In isogenic pairs of PI sensitive and resistant cells, we observed stark differences in cellular bioenergetics between the divergent phenotypes. PI resistant cells exhibited increased mitochondrial respiration driven by glutamine as the principle fuel source. To target glutamine-induced respiration in PI resistant cells, we utilized the glutaminase-1 inhibitor, CB-839. CB-839 inhibited mitochondrial respiration and was more cytotoxic in PI resistant cells as a single agent. Furthermore, we found that CB-839 synergistically enhanced the activity of multiple PIs with the most dramatic synergy being observed with carfilzomib (Crflz), which was confirmed in a panel of genetically diverse PI sensitive and resistant MM cells. Mechanistically, CB-839 enhanced Crflz-induced ER stress and apoptosis, characterized by a robust induction of ATF4 and CHOP and the activation of caspases. Our findings suggest that the acquisition of PI resistance involves adaptations in cellular bioenergetics, supporting the combination of CB-839 with Crflz for the treatment of refractory MM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.16262

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

Metadata

Authors
Thompson, R. M., Dytfeld, D., Reyes, L., Robinson, R. M., Smith, B., Manevich, Y., Jakubowiak, A., Komarnicki, M., Przybylowicz-Chalecka, A., Szczepaniak, T., Mitra, A. K., Van Ness, B. G., Luczak, M., & Dolloff, N. G.
Venue
Oncotarget
Published
2017-05-30
Volume
8
Issue
22
Pages
35863-35876
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2597387377
Cited by
126
References
15
FWCI
7.60
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.